Abstract:COVID-19 has affected more than half a billion people worldwide, with more than 6.3 million deaths, but the pathophysiological mechanisms involved in lethal cases and the host determinants that determine the different clinical outcomes are still unclear. In this study, we assessed lung autopsies of 47 COVID-19 patients and examined the inflammatory profiles, viral loads, and inflammasome activation. Additionally, we correlated these factors with the patient's clinical and histopathological conditions. Robust inflammasome activation was detected in the lungs of lethal cases of SARS-CoV-2. Experiments conducted on transgenic mice expressing hACE2 and infected with SARS-CoV-2 showed that Nlrp3 -/- mice were protected from disease development and lethality compared to Nlrp3 +/+ littermate mice, supporting the involvement of this inflammasome in disease exacerbation. An analysis of gene expression allowed for the classification of COVID-19 patients into two different clusters. Cluster 1 died with higher viral loads and exhibited a reduced inflammatory profile than Cluster 2. Illness time, mechanical ventilation time, pulmonary fibrosis, respiratory functions, histopathological status, thrombosis, viral loads, and inflammasome activation significantly differed between the two clusters. Our data demonstrated two distinct profiles in lethal cases of COVID-19, thus indicating that the balance of viral replication and inflammasome-mediated pulmonary inflammation led to different clinical outcomes. We provide important information to understand clinical variations in severe COVID-19, a process that is critical for decisions between immune-mediated or antiviral-mediated therapies for the treatment of critical cases of COVID-19. Although the SARS-CoV-2 pandemic has significantly affected the worldwide population and contributed to the death of millions worldwide, the processes that lead to patient death are still obscure. In this study, we assessed lung autopsies of 47 fatal cases of COVID-19 and found a significant activation of the NLRP3 inflammasome in the lungs of patients. To investigate whether this correlation between NLRP3 activation and disease exacerbation implies a cause-and-effect relationship, we performed infections in transgenic mice expressing the human ACE2 receptor. These mice were successfully infected with SARS-CoV-2, and we demonstrated that Nlrp3 -deficient mice were protected from disease development and lethality compared to littermate animals sufficient for NLRP3, indicating a cause-consequence effect. Moreover, we found that patients who succumbed to COVID-19 can be divided into two main groups: Cluster 1, composed of patients who died with higher viral loads and reduced inflammation in the lungs, as opposed to patients from Cluster 2. We found that pulmonary thrombosis and disseminated intravascular coagulation were higher in patients from Cluster 1, contrasting with the significant development of fibrosis and hyperinflammation in Cluster 2 patients. Our study demonstrates the existence of two distinct profiles in lethal cases of COVID-19, a feature that is important to our understanding of lethality in this disease. Understanding these processes will be important to direct future therapeutic strategies for severe cases of COVID-19, either to target viral replication and thrombosis or to target the excessive inflammatory process.

The pulmonary vasculature in lethal COVID-19 and idiopathic pulmonary fibrosis at single-cell resolution

A Molecular Single-Cell Lung Atlas of Lethal COVID-19.

SARS-CoV-2 Infection Triggers Profibrotic Macrophage Responses and Lung Fibrosis

Molecular and immune signatures, and pathological trajectories of fatal COVID-19 lungs defined by in situ spatial single-cell transcriptome analysis

A single-cell transcriptomic landscape of the lungs of patients with COVID-19

Procoagulant phenotype of virus-infected pericytes is associated with portal thrombosis and intrapulmonary vascular dilations in fatal COVID-19

COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets

Fulminant lung fibrosis in non-resolvable COVID-19 requiring transplantation

Diffuse alveolar damage patterns reflect the immunological and molecular heterogeneity in fatal COVID-19

Endothelial cell infection and dysfunction, immune activation in severe COVID-19

Pulmonary inflammation and viral replication define distinct clinical outcomes in fatal cases of COVID-19

A single-cell and spatial atlas of autopsy tissues reveals pathology and cellular targets of SARS-CoV-2

Differential Transcriptomic Signatures of Small Airway Cell Cultures Derived from IPF and COVID-19-Induced Exacerbation of Interstitial Lung Disease

Immunohistochemical and Morphometric Analysis of Lung Tissue in Fatal COVID-19

Spatial transcriptomics unveils the in situ cellular and molecular hallmarks of the lung in fatal COVID-19

Common and rare variant analyses reveal novel genetic factors underlying Idiopathic Pulmonary Fibrosis and shared aetiology with COVID-19

Endothelial Permeability and the Angiopoietin/Tie2 System Following Mild and Severe COVID-19

Neutrophil Activity and Extracellular Matrix Degradation: Drivers of Lung Tissue Destruction in Fatal COVID-19 Cases and Implications for Long COVID

Distinct tissue niches direct lung immunopathology via CCL18 and CCL21 in severe COVID-19

COVID-19 lung disease shares driver AT2 cytopathic features with Idiopathic pulmonary fibrosis

Transcriptional and proteomic insights into the host response in fatal COVID-19 cases